A spokesman for UnitedHealth Group said that the mother of Mangione, a suspect accused of shooting a company executive, also had no insurance for UnitedHealth.Morgan Stanley called concerns about South Korean financial stocks "excessive". Morgan Stanley said that recent political developments have hit South Korean financial stocks particularly hard because people are worried that reform efforts may be delayed and the risk of tightening supervision.The American medical insurance giant said that the suspect who assassinated its CEO was not a company customer. A spokesman for UnitedHealth Group said that Luigi Mangione, the suspect accused of killing Brian Thompson, CEO of the company's United Health Care, was not a member of the company's insurance plan. Unitedhealth group said that Man Ghione and his mother were not members of United Health Insurance Company, and refuted the claim that the shooting incident was caused by dissatisfaction caused by his special experience in the company.
Onlikon: The cooperative product Aidit calcitonin soft capsules is planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13th, and on December 12th, the company received a notice from its partner Beijing Meifurun Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Meifurun") that the Aidit calcitonin soft capsules jointly developed by the company and its wholly-owned subsidiary Wenzhou Haihe Pharmaceutical Co., Ltd. are planned to be selected for the tenth batch of national centralized drug procurement. According to the Pharmaceutical Cooperation Agreement signed by the company and its partner Mei Furun, the company owns 50% of the cooperative products.Japanese and Korean stock markets opened lower, with the Nikkei 225 index down 0.56% at 39,624.05. South Korea's KOSPI index opened down 0.3% to 2,473.75 points.Haitong Securities: The moderate price reduction of traditional Chinese medicine varieties continues. The domestic pharmaceutical industry is expected to set off a wave of mergers and acquisitions. Haitong Securities released a research report saying that the moderate price reduction of traditional Chinese medicine varieties continues. In 2024, the traditional Chinese medicine industry was under pressure due to the pressure of pharmacy terminal sales and inventory pressure, and it is expected to return to a good situation in the next 25 years. In addition, the continuous technological changes in the pharmaceutical industry, the development of IPO to mergers and acquisitions and the promotion of corporate governance optimization at the shareholder level are the main reasons for promoting mergers and acquisitions in the industry. In terms of fields, mergers and acquisitions are expected to occur intensively in sub-sectors such as medical devices, Chinese medicine, medical services, blood products and scientific research services.
CICC: Cloud and terminal AI landing In 2025, the localization of semiconductors and components ushered in a new cycle. According to CICC's research report, in 2024, semiconductors and components as a whole were in the upward stage of prosperity. It is expected that inventory, supply and demand will stabilize in 2025, and AI cloud and terminal demand will land, and domestic elements will usher in a new cycle. It is expected that in 2025, the AI replacement tide is expected to accelerate the downstream demand growth of the semiconductor design sector. We are optimistic about the demand expansion of cloud and end-side computing chips driven by AI, and the alpha level of individual stocks is optimistic about the pull of product structure expansion on the performance of related companies, and it is suggested to pay attention to the investment opportunities brought by mergers and acquisitions for some tracks. It is expected that the supply and demand of chip manufacturing will approach a balance in 2025, and the capacity utilization rate will remain at a reasonable level; Among them, the research and development of advanced process manufacturing is expected to continue to advance, driving the development of equipment, parts, materials and design tools.Google released the Android XR operating system, and Samsung's first launch will be launched next year. On December 12, local time, Google launched a new operating system Android XR developed in cooperation with Samsung, which combines years of investment in AI, AR and VR, aiming at wearing devices and smart glasses. Bring a practical experience. This release is a preview for developers, who can start to develop applications and games for the upcoming Android XR device. The first head-mounted display device developed based on Android XR is code-named "Project Moohan", which is made by Samsung and will go on sale next year.Macquarie Asset Management is considering selling its Indian highway portfolio.
Strategy guide
12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide
12-14